References
- Rigel DS, Stein Gold LF. The importance of early diagnosis and treatment of actinic keratosis. J Am Acad Dermatol. 2013;68:S20–S7.
- Werner RN, Sammain A, Erdmann R, et al. The natural history of actinic keratosis: a systematic review. Br J Dermatol. 2013;169:502–18.
- Roewert-Huber J, Stockfleth E, Kerl H. Pathology and pathobiology of actinic (solar) keratosis – an update. Br J Dermatol. 2007;157:18–20.
- Berman B. New developments in the treatment of actinic keratosis: focus on ingenol mebutate gel. Clin Cosmet Investig Dermatol. 2012;5:111–22.
- Werner RN, Stockfleth E, Connolly SM, et al. Evidence and consensus based (S3) guidelines for the treatment of actinic keratosis. 2015. Available from: http://www.euroderm.org/edf/index.php/edf-guidelines/category/5-guidelines-miscellaneous?download=23:guideline-management-of-actinic-keratoses-update-2015. Accessed August 28, 2015.
- Hofbauer GF, Anliker M, Arnold A, et al. Swiss clinical practice guidelines for skin cancer in organ transplant recipients. Swiss Med Wkly. 2009;139:407–15.
- Rosen R, Marmur E, Anderson L, et al. A new, objective, quantitative scale for measuring local skin responses following topical actinic keratosis therapy with ingenol mebutate. Dermatol Ther (Heidelb). 2014;4:207–19.
- LEO, Pharma Picato® (ingenol mebutate) gel, 0.015%, 0.05%. Prescribing information. 2012. Available from: http://www.picato.com/_pdf/PrescribingInformation.pdf. Accessed August 10, 2015.
- Lebwohl M, Swanson N, Anderson LL, et al. Ingenol mebutate gel for actinic keratosis. N Engl J Med. 2012;366:1010–9.
- Anderson L, Jarrett M, Schmieder G, et al. Tolerability and pharmacokinetics of ingenol mebutate 0.05% gel applied to treatment areas up to 100cm2 on the forearm(s) of patients with actinic keratosis. J Clin Aesthet Dermatol. 2014;7:19–29.
- (FDA) FaDA. Clinical Pharmacology and Biopharmaceutics Review of Ingenol Mebutate FDA CDER. 2012 [16 February 2016]. Available form: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202833Orig1s000ClinPharmR.pdf
- Ceilley RI, Jorizzo JL. Current issues in the management of actinic keratosis. J Am Acad Dermatol. 2013;68:S28–S38.
- Uhlenhake EE. Optimal treatment of actinic keratoses. Clin Interv Aging. 2013;8:29–35.
- (FDA) FaDA. Guidance for industry and FDA staff: review criteria for assessment of c-reactive protein (CRP), high sensitivity c-reactive protein (hsCRP) and cardiac c-reactive protein (cCRP) assays. Silver Spring, MD: US Center for Devices and Radiological Health; 2005. Available from: https://www.fda.gov/MedicalDevices/ucm077167.html
- Campalani E, Holden CA. Keratoacanthoma associated with the use of topical imiquimod. Clin Exp Dermatol. 2013;38:555–6.
- Cox S. Rapid development of keratoacanthomas after a body peel. Dermatol Surg. 2003;29:201–3.
- Kaptanoglu AF, Kutluay L. Keratoacanthoma developing in previous cryotherapy site for solar keratosis. J Eur Acad Dermatol Venereol. 2006;20:197–8.
- Selmer J, Skov T, Spelman L, Weedon D. Squamous cell carcinoma and keratoacanthomas are biologically distinct and can be diagnosed by light microscopy: a review. Histopathology. 2016;69:535–41.